GE HealthCare has gained simultaneous US Food and Drug Administration (FDA) clearance and a European CE mark for Allia Moveo, setting healthcare centres up with an imaging system intended to facilitate greater procedural flexibility in the interventional suite.
A new offering within the imaging giant’s Allia product line, Moveo has been designed to help streamline clinicians’ workflows and cater to more diverse patient populations.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
With a more compact form factor than previous iterations of its Allia range, and a cable-free, wide-bore C-arm for cone beam computed tomography (CBCT), GE HealthCare anticipates that Moveo will ensure patients with a broader range of body sizes are equally comfortable throughout minimally invasive procedures.
Meanwhile, Moveo is equipped with imaging technology including CleaRecon DL and Motion Freeze. The former is an artificial intelligence (AI) tool for removing streak artifacts caused by arterial blood flow that received FDA clearance and a CE mark in May 2025, while the latter is designed to offset involuntary respiratory motion artifacts to improve image clarity. GE HealthCare anticipates that these and other tools embedded in the system will help clinicians to navigate complex minimally invasive procedures with greater efficiency.
Initially unveiled at the Radiological Society of North America’s (RSNA) 2025 Annual Meeting in December 2025, France’s Hôpital Marie-Lannelongue in Le Plessis-Robinson has become the world’s first healthcare centre to complete an install of Allia Moveo.
Arnaud Marie, general manager of interventional solutions at GE HealthCare commented: “We are excited to collaborate with leading experts at Hôpital Marie-Lannelongue on the first installation of this system, which is a defining step forward for care in the interventional suite, and a testament to our shared commitment to advancing meaningful innovation with the goal of supporting better outcomes for care teams and the patients they treat.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataGE HealthCare’s forward outlook
In terms of product launches and partnerships, GE HealthCare is one of the most active companies within the medtech space. Throughout 2025, the company’s product launches and initiatives included partnering with the University of Rochester Medical Center (URMC) to advance healthcare capabilities across the university’s facilities, the launch of a new cloud-native radiology management system to advance diagnostic workflows, and the launch of a new cardiovascular ultrasound system that integrates AI to enhance imaging speed and quality.
Speaking at the recent J.P. Morgan Healthcare conference, regarding GE HealthCare’s future outlook, CEO Peter Arduini highlighted that over time, the company wants to be measured less as an imaging hardware vendor, and as more of a healthcare solutions provider.
In contextualising this viewpoint, Arduini pointed to the fact GE HealthCare has taken steps to simplify its CT portfolio, slimming it down from around 15 configurations and 10 tables to three in recent years, with the chief aim of this action being to reduce complexity for customers and lower internal costs.
AI is having an outsized influenced on healthcare, particularly within the imaging space, where the technology has found numerous applications in streamlining efficiencies and improving imaging quality. According to GlobalData analysis, AI in healthcare is forecast to reach a $19bn valuation by 2027.
